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HIGHLIGHTS 
 Mesenchymal stem cells (MSCs) are of interest for the treatment of brain pathologies 
 Spatial memory in aged female rats significantly improved after MSC administration 
 Hippocampal neurogenesis increased after MSC treatment in aging rats 

















There is a growing interest in the potential of mesenchymal stem cells (MSCs) for implementing 
regenerative medicine in the brain as they have shown neurogenic and immunomodulatory activities. 
We assessed the effect of intracerebroventricular (icv) administration of human bone marrow-derived 
MSCs (hBM-MSCs) on spatial memory and hippocampal morphology of senile (27 months) female 
rats, using 3-months-old counterparts as young controls. Half of the animals were injected in the 
lateral ventricles (LV) with a suspension containing 5 X 105hBM-MSCs in 8µl per side. The other 
half received no treatment (senile controls). Spatial memory performance was assessed with a 
modified version of the Barnes maze test. We employed one probe trial, one day after training in 
order to evaluate learning ability as well as spatial memory retention. Neuroblast (DCX) and 
microglial (Iba-1 immunoreactive) markers were also immunohistochemically quantitated in the 
animals by means of an unbiased stereological approach. In addition, hippocampal presynaptic 
protein expression was assessed by immunoblotting analysis. After treatment, the senile MSC-treated 
group showed a significant improvement in spatial memory accuracy and extended permanence in a 
one- and 3-hole goal sectors as compared with senile controls. The MSC treatment increased the 
number of neuroblasts in the hippocampal dentate gyrus, reduced the number of reactive microglial 
cells, and restored presynaptic protein levels as compared to senile controls. We conclude that icv 
injected hBM-MSCs are effective in improving spatial memory in senile rats and that the strategy 
improves some functional and morphologic brain features typically altered in aging rats. 
 
Keywords. Brain aging- memory- hippocampus- mesenchymal stem cells – cell therapy 
 
1.-INTRODUCTION 
There is a growing interest in the therapeutic potential of adult mesenchymal stem cells (MSCs) in 
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derived MSCs. They are known to secrete neurotrophic factors and promote the survival, 
proliferation and differentiation of neural cells in vitro [1, 2]. See Discussion for further details on 
the neuroactive factors released by MSC.  
MSCs are easily isolated and expanded from bone marrow and even from adipose tissues, amniotic 
fluid, endometrium, dental tissues, umbilical cord. They are multipotent adult stem cells with the 
capacity to differentiate into mesodermal lineage such as osteocytes, adipocytes and chondrocytes[3]. 
However, MSCs also show differentiation plasticity into other endodermal lineages (hepatocytes) 
and ectodermal (neurocytes), including neurons and glial cells [4]. In addition to their neural 
differentiation ability under special conditions, MSCs are known for their capacity to promote 
neurogenesis of primary neural progenitors and survival of neural cells, by expressing neurotrophic 
factors, such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and insulin-
like growth factor-1 [5, 6]. The level of these neurotrophic factors is severely affected in aging and 
can be correlated with cognitive decline [7, 8]. 
Transplantation of MSCs in the central nervous system prevents apoptosis and promotes 
neurogenesis (proliferation and differentiation) of ‘host’ neural cells and stem cells in the engrafted 
site [5, 9, 10]. MSCs were therefore suggested as candidates for treating a variety of 
neurodegenerative diseases, in particular Parkinson’s disease (PD), multiple sclerosis, cerebral 
hemorrhage and brain cancer [11–13]. Intracerebroventricular (icv) injection of bone marrow-derived 
MSCs increased hippocampal neurogenesis in a rat model of depression. Thus, after transplantation, 
MSCs migrated mainly to the dentate gyrus (DG), CA1 and CA3 regions of the hippocampus, and to 
a lesser extent to the thalamus, hypothalamus, cortex and contralateral hippocampus. Neurogenesis 
was increased in the ipsilateral DG of engrafted rats (granular cell layer). The level of engraftment 
was positively correlated with behavioral performance [14]. Sites such as the hippocampus, 
subventricular zone and optic bulb, where active neurogenesis occurs in adulthood, are often 
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In females Sprague-Dawley (SD) rats, spatial memory impairment begins at 14 months, with greater 
impairment at 20 to 26 months [17]. Furthermore, immune reactivity and inflammatory processes 
increase with aging in the brain [18], with microglia playing a central role in this immune 
dysregulation [19, 20]. We have recently shown that in aging female rats there is a significant 
activation of reactive microglia and identified a cluster of hippocampal immune genes that are 
dysregulated in the aged animals [21]. Interestingly, it was reported that MSCs are able to maintain 
the resting phenotype of microglia and can also control its activation through the release of several 
factors, including but not limited to, vascular endothelial growth factor (VEGF), brain-derived 
neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF) and hepatocyte growth 
factor (HGF), which suggests that MSCs could be a promising therapeutic tool for treatment of 
diseases associated with microglial activation [22]. The above information prompted us to explore 
the neuroprotective potential of human bone marrow-derived MSCs (hBM-MSCs) in the 
hippocampus of senile rats at both functional and morphological level. 
 
2.- MATERIALS AND METHODS 
2.1- Human bone marrow-derived mesenchymal stem cells 
Human BM-MSCs were isolated from bone marrow aspirates of healthy donors for allogeneic 
transplantation after informed consent approved by the Institutional Review Committee of Hospital 
Naval Pedro Mallo and Fundación Instituto Leloir, Argentina and according to the International 
Society for Cellular Therapy (ISCT) guidelines. Human MSCs were characterized as described 
previously [23], cultured in complete DMEM low glucose (2 μM glutamine, 100 U/ml penicillin, 100 
mg/ ml streptomycin) and 20% heat- inactivated fetal bovine serum (FBS), and used between 
passages 4 to 7. 
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Human BM-MSCs cultures were grown in Petri dishes to 90% confluence. Suspended MSCs were 
labeled with 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlorate (Dil, Sigma Chem 
Co.) fluorescent dye (stock solution: 0.25 µg of Dil per microliter of dimethylsulfoxide). Briefly, 
trypsinized MSCs were suspended in phosphate buffered saline (PBS, 106 cells/ml) in the presence 
of Dil at a final concentration of 1 µg/ml and incubated for 5 min at 37°C followed by 15 min at 4°C 
and finally washed 3 times with PBS. An appropriate dilution (6.25 X 104 MSCs/µl) for the icv 
injection was made. 
 
2.3- Animals and experimental design 
Young (3 mo.) and senescent (27 mo.) female SD rats were used. The animals were housed in a 
temperature-controlled room (22 ± 2ºC) on a 12:12 h light/dark cycle. Food and water were available 
ad libitum. All experiments with animals were performed in accordance to the Animal Welfare 
Guidelines of NIH (INIBIOLP’s Animal Welfare Assurance No A5647-01). 
Rats were grouped, as follows: Group Yc, consisted of 8 young rats that received no treatment. 
Group Sc, consisted of 8 senescent rats that received no treatment and Group Smsc, consisted of 8 
senescent rats that were stereotaxically injected with MSCs. 
The day of MSCs injection was defined as experimental day 0. Before and after cell injection, a full 
Barnes maze test, comprising 6 acquisition trials (AT) and a probe trial was performed on all rats. 
Additional young rats were used for time-course studies. 
Experimental design- Nine days before the MSCs injection (experimental day -9) the pre-treatment 
Barnes maze test began. On experimental day 0, old rats were icv injected with MSCs as described 
below. From experimental day 15 to 18, all rats were submitted to the post-treatment Barnes maze 
test (Fig 1 A). On experimental day 21, all rats were euthanized as described below. 
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experimental day 0, rats were icv injected with Dil-labeled MSCs as described below. At different 
time-points, on experimental day 5, 11, 14 and 21, two rats were sacrificed as described below. 
Brains were processed as previously described for immunohistochemical assessment to analyze the 
distribution and permanence of injected cells (Fig 1 B). 
 
2.5- Stereotaxic injections 
Rats were anesthetized with ketamine hydrochloride (40 mg/kg; ip) plus xylazine (8 mg/kg; im) and 
placed in a stereotaxic apparatus. In order to access the LV, the tip of a 26G needle fitted to a 10 µl 
syringe was brought to the following coordinates relative to the bregma: -0.8 mm anteroposterior, 4.1 
mm dorsoventral and ±1.5 mm mediolateral [24]. The animals were injected bilaterally with 8 µl per 
side of a suspension containing 5 X 105 MSCs. 
 
2.6- Spatial memory assessment 
A modified Barnes maze protocol was used in this study; it is based on a previously reported 
procedure [25]. It consists of an elevated (108 cm to the floor) black acrylic circular platform, 122 
cm in diameter, containing twenty holes around the periphery. The holes are of uniform diameter (10 
cm) and appearance, but only one hole is connected to a black escape box (tunnel). The escape box is 
38.7 cm long x 12.1 cm wide x 14.2 cm in depth and it is removable. A white cylindrical starting 
chamber (an opaque, 20 cm x 30 cm long, and 15 cm high, open-ended chamber) is used to place the 
rats on the platform. Four proximal visual cues are placed in the room, 50 cm away from the circular 
platform. The escape hole was numbered as hole 0 for graphical normalized representation purposes, 
the remaining holes being numbered 1 to 10 clockwise, and −1 to −9 counterclockwise (Fig 3A).  
Hole 0 remained in a fixed position, relative to the cues in order to avoid randomization of the 
relative position of the scape box. During the test, the platform was rotated daily. A90-dB white-
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We used an shortened protocol based on three days of acquisition trials (AT), followed by a probe 
trial, 1 day after training, to assess recent spatial memory retention [26]. An acquisition trial consists 
of placing a rat, randomly oriented, in the starting chamber for 30 s, the chamber is then raised, the 
aversive stimuli are switched on and the rat is allowed to freely explore the maze for 120 s. Probe 
traial is defined as a trial where the escape box has been removed, its purpose being to assess the 
latency to explore the empty escape hole and the error frequency. After the starting chamber is 
raised, the rat is given 120 s to explore and the number of explorations per hole is recorded. In order 
to eliminate olfactive clues from the maze and the boxes, the surfaces are cleaned with 10% ethylic 
alcohol solution, after each trial. On the day before acquisition trial, animals were habituated to the 
starting chamber and escape box by placing them inside each one for 180s. 
The behavioral performances were recorded using a computer-linked video camera mounted 110 cm 
above the platform. The video-recorded performances of the subjects were measured using the 
Kinovea v0.7.6 (http://www.kinovea.org) software. The behavioral parameters assessed were as 
follows. 
Escape box latency: time (in s) spent by an animal since its release from the starting chamber until it 
enters the escape box (during an acquisition trial) or until the first exploration of the escape hole 
(during a probe trial). 
Goal sector exploration frequency (GS): the sum of the number of explorations for holes −1, 0, 
and 1 divided by 3 (GS3) or the number of explorations of hole 0 (GS1), during a probe trial. 
GS3 progression index: this parameter results from the difference between the frequency of final 
(post-treatment) minus the initial exploration(pre-treatment). 
 
2.7- Sample preparation 
Animals were placed under deep anesthesia and transcardially perfused with phosphate buffered 
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formaldehyde 4%, (pH 7.4) overnight (4 ºC). Finally, brains were maintained in cryopreservative 
solution (30% ethylene glycol, 1% polyvinylpyrrolidone, 30% sucrose, in phosphate buffer 0.1 M, 
pH 7.4) at -20 ºC until use. For immunohistochemical assessment, brains were cut coronally in 40 
µm-thick sections with a vibratome (VT1000S; Leica Microsystems, Wetzlar, Germany). The rest of 
the animals were quickly decapitated, and the hippocampus carefully dissected as previously 
described [27] and stored at -80 °C until WB analysis. 
 
2.8- Immunohistochemistry 
All immunohistochemical techniques were performed on free-floating sections. For each animal, 
separate sets of sections were immunohistochemically processed using anti-doublecortin (DCX) goat 
polyclonal antibody 1:250 (c-18, Santa Cruz Biotech., Dallas, Texas) and anti-Iba-1 rabbit polyclonal 
antibody 1: 1000 (016-20001, Wako Chemicals, Richmond, VA, USA). For detection, the 
Vectastain® Universal ABC kit (1:500, PK-6100, Vector Labs., Inc., Burlingame, CA, USA) 
employing 3, 3-diamino benzidine tertrahydro-chloride (DAB) as chromogen, was used. Briefly, 
after overnight incubation at 4ºC with the primary antibody, sections were incubated with 
biotinylated horse anti-mouse antiserum (1:300, BA- 2000,Vector Labs.) or horse anti-goat 
antiserum (1:300, BA-9500, Vector Labs), as appropriate, for 120 min, rinsed and incubated with 
avidin-biotin-peroxidase complex (ABC Kit) for 90 min and then incubated with DAB. Sections 
were counterstain with Nissl method (0.5% cresyl violet solution at 37ºC for 10 min) to visualize 
anatomical landmarks and mounted with Vectamount (Vector Labs) to use for image analysis. 
 
 
2.9- Image Analysis 
In each hippocampal block, every sixth serial sections were selected in order to obtain a set of non-
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assessed in the dorsal hippocampus which is located between coordinates -2.8 mm to -4.5 mm from 
the bregma [24] using an Olympus BX-51 microscope, at 500X magnification, attached to an 
Olympus DP70 CCD video camera (Tokyo, Japan). The total number of cells was estimated using 
a modified version of the optical dissector method [28]. Individual estimates of the total bilateral cell 
number (N) were calculated according to the following formula: N = RQΣ · 1/ ssf · 1/asf · 1/tsf, 
where RQΣ is the sum of counted cells, ssf is the section sampling fraction, asf is the area sampling 
fraction, and tsf is the thickness sampling fraction. 
 
2.10- Neuroblast analysis 
The number of DCX positive neuroblasts was assessed using a modified version of the optical 
fractionator technique [28]. The entire subgranular zone (SGZ) and granular cell layer (GCL) regions 
were quantified (8 sections per animal), with asf=1, ssf=1/6 and tsf=1. Estimates were based on 
counting DCX(+) cell bodies as they came into focus. N= 4 animals per group. 
 
2.11- Microglial cell analysis 
Microglial cells were identified as Iba-1 immunoreactive cells. Iba-1 immunoreactive cells were 
counted in the Srad of the CA1 region of the dorsal hippocampus. The Srad upper limit is the 
pyramidal layer, lower limit is Stratum Lacunosum Moleculare and the lateral limit is the Stratum 
Lucidum [24]. To this end, a random grid consisting of squared probes (area=22,500 µm2) was 
superimposed over calibrated images taken at 600X magnification (3 fields per section, 6-8 sections 
per animal) and cells inside the probe area were counted. Cells making contact with boundary 
inclusion lines of the probes were included in the count, whereas cells in contact with boundary 
exclusion lines were not counted. Iba-1 immunoreactive cells were morphologically classified as 
type I, II, III, IV and V on the basis of previously documented criteria [26, 29]. Type I, cells with few 
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with numerous (>5) and longer cell processes and a small cell body; Type IV, cells with large somas 
and retracted and thicker processes and Type V, cells with amoeboid cell body, numerous short 
processes and intense Iba-1 immunostaining. Types I, II and III were categorized as nonreactive glia 
whereas types IV and V were taken as reactive glia. Reactive microglial cell number/section was 
calculated for each animal with asf=0.387, ssf=1/6, and tsf=1. N= 4 animals per group. 
 
2.12 Western Blot Analysis 
2.12.1 Sample preparation 
In order to obtain protein lysates, hippocampi were homogenized with precooled RIPA buffer (150 
mM NaCl, 1% Triton X-100, 0.5 % sodium deoxycolate, 0.1 % SDS, 50 mM Tris-HCl pH 8, and 
appropriate protease inhibitors, pH 7.4). Finally, protein concentration was measured by Bradford 
protein assay. Bovine serum albumin (BSA) (0.1-1 mg/ml) was used as a standard. Samples were 
aliquoted and stored at -80°C. 
 
2.12.2 Immunoblotting 
Equal amounts of protein (50 μg) for every sample were separated by 10% SDS-PAGE and 
transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked by incubation in 
5% non-fat milk in Tris-buffered saline/Tween-20 (TBS-T) for 1 h at room temperature, and then 
incubated with primary antibodies against Synaptotagmin 1 (SYT1, 1:200; mAb 48, DSHB), 
Synaptophysin (SYP, 1:200; sc-17750, Santa Cruz Biotech.), Postsynaptic density protein 95 (PSD-
95, 1:200, sc-32290, Santa Cruz Biotech.), Vinculin (VIN) (1:200; sc-73614, Santa Cruz Biotech.) 
and β-Actin (1:1000, sc-47778, Santa Cruz Biotech.) overnight at 4°C. Then, the membranes were 
washed with TBS-T and incubated with anti-mouse secondary antibody conjugated with horseradish 
peroxidase (1:10000, #115-035-003, Jackson ImmunoResearch Laboratories) for 3 h at room 
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West Pico PLUS Chemiluminescent substrate (#34577, Thermo Fisher Scientific) on a Chemidoc 
Image Station (Bio-Rad, Hercules, CA, USA). Relative optical density of protein bands was 
analyzed using gel documentation system. Sample loading was normalized to relative density of VIN 
or β-Actin band. Four rats per group were used for the WB . 
 
2.13 -Statistical analysis 
Data were compiled and analyzed with the Sigma Plot v. 11 software (San Jose, CA). The analysis of 
repeated measurements (rm) of ANOVA was applied over the data obtained from behavioral tests. 
Wilcoxon matched-pairs signed rank test was employed for GS3 analysis. For determine MSCs 
rejuvenated effect ANOVA was used (Iba-1 immunohistochemistry and SYT1 immunoblotting). 
Otherwise, stereological assessment of senile groups data was examined by Unpaired Student t-test. 
All data are r e presented as mean ± SEM. Holm-Sidak and Tukey’s post-hoc tests were used where 
appropriate. Criteria for significant differences were set at 95% probability level. 
 
3.-RESULTS 
3.1- Time-course of MSC in the cerebral ventricles 
Dil-fluorescence in coronal sections of MSCs-injected young brains revealed that five days after 
injection, Dil-labeled hBM-MSCs were located in close contact with the ependymal cells. The 
number of labeled cells decreased progressively from experimental day 5. On the day of sacrifice 
(21) labeled cells were still observable close to the ependymal layers (Fig 1B). However, some of 
these cells traveled a short distance from the ventricular spaces to the parenchyma (Fig 1B). 
 
3.2- Cognitive Changes 
3.2.1- Hole exploration frequency- As expected, hole exploration frequency showed a bell-shaped 
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2). However, the shape of the bell was less well-defined in old than in young rats. The amplitude of 
the bell was higher in the young animals (insets to Fig 2A and 2B). At pretreatment, the shape and 
amplitude of hole exploration frequency was comparable in both senile groups (P=0.1), and the hole 
0 exploration frequency was significantly different than the rest of the holes in both senile groups 
(Fig 2-A, P<0.0001). After treatment, the shape and amplitude of hole exploration frequency was 
significantly different between Sc and Smsc groups (P=0.045) with a major preference for holes 
neighboring goal hole than farther holes (Fig 2-B, P<0.0001). Notice that hole 0 exploration 
frequency of Smsc group was significantly higher than in Sc rats (P<0.01). Also, there is a 
statistically significant interaction between treatment and hole position (P=0.008).  
3.2.2- Goal sector exploration- The hole exploration frequency of senile rats before and after MSC 
treatment was assessed and compared in different goal sectors. In GS1 Sc rats showed no significant 
difference before and after experimental day 0 (P=0.116) whereas MSC treatment induced a 
significant increase in GS1 exploration (Fig 3-B, P=0.016). In the case of GS3, exploration 
frequency both old rat groups showed a significant difference before and after experimental day 0 
(P=0.016). In the Smsc rats, treatment induced a significant increase in GS3 exploration frequency 
(Fig 3-C, P=0.015). When as compared progression in the GS3 exploratory frequency (pos-treatment 
- pre-treatment), Smsc rats presented an improvement in this parameter but Sc rats showed an 
impaired behavior (Fig 3-D, P=0.001). 
 
3.3 Morphometric Changes 
3.3.1- Effects of MSCs treatment on hippocampal morphometry in old rats 
A stereological assessment of neuroblasts and microglial cells was performed in the dorsal 
hippocampus of young and senile control rats as well as in MSCs-treated aged rats. There was a 
significant increase in the number of DCX cells (neuroblasts) in the DG of MSC-treated senile 
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D, P=0.042). As expected, the number of DCX neurons in the same region was much higher in 
young than in old rats (Fig 4-D inset). Hippocampal microglial cells were classified as non-reactive 
and reactive and were counted in the Stratum Radiatum (Srad). As expected, the number of reactive 
microglial cells increased with age but in the senile rats MSC treatment induced a significant 
decrease in the number of reactive Iba-1 immunoreactive cells as compared with senile control 
counterparts (Fig 5-D, P=0.075). Non-reactive microglial cell number in the MSC-treated senile rats 
was significantly increased as compared with senile controls (Fig. 5-E, P=0.002). MSC treatment 
induced no significant changes in total Iba-1 immunoreactive cells (Fig 5-F, P=0.076). 
 
3.4 Synaptic protein changes after icv-MSCs administration 
In order to explore the effect of MSCs in the senile hippocampus synapses, we determined the 
protein levels of tree synaptic proteins by Western blot (WB) analysis (Fig. 6-A). SYP, a polypeptide 
component of small presynaptic transmitter-containing vesicles in neurons [30], neither age nor 
treatment induced changes in SYP levels (Fig. 6-B, P=0.588). However, SYT1, a synaptic vesicle-
associated membrane protein that acts as calcium sensor for fast neurotransmitter release from 
presynaptic nerve terminals [31], showed significant decrease in senile rats (Fig. 6-C, P=0.001). 
Also, PSD-95, a membrane-associated guanylate kinase (MAGUK), that is the major scaffolding 
protein in the excitatory postsynaptic density and a potent regulator of synaptic strength [32], showed 
significant decrease in senile rats (Fig. 6-D, P=0.0423). 
 
4.-DISCUSSION 
Previous studies have shown that lifelong intravenous (iv) injection of amniotic membrane-derived 
hMSCs (AM-MSCs) or adipose tissue-derived MSCs (AD-MSCs) to 10-month-old male F344 had 
life-extending effects. The AM-MSCs and AD-MSC improved cognitive and physical functions of 
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well as results from others [34] and from our group suggest that MSCs possess the ability to slow 
down the age-related decline typical of higher animal species when the treatment is begun during 
adulthood. Thus, we have demonstrated that lifelong iv injection of hMSCs begun in a rat at 6 
months of age, markedly prolonged (22%) lifespan (44 months versus the typical 36 months of 
standard laboratory rats [35, 36]). In the present study we focused our work on the effect of MSC 
treatment when begun in already old rats, in an attempt to determine whether administration of hBM-
MSCs to aged rats could be able to restore their deficient cognitive performance and altered 
hippocampal morphology. Although the main goal of the study was to assess the possible restorative 
effects of MSC on spatial memory performance and hippocampal neurogenesis in old rats, the fact 
that an exploration of the restorative effects of mesenchymal cell therapy has, to our knowledge, 
never been reported in old rats prompted us to explore the effect of MSC-treatment in another 
relevant cell population, the microglia. Since old rats are highly valuable animals, we screened a 
number of structural and cellular features in the hippocampus of these rats and found that, besides 
spatial memory performance, microglial activity was also rescued by the treatment. Consequently, 
we deemed that reporting on the beneficial effect of the treatment on microglial reactivity was a 
valuable addition.  
We chose the ependymal route of administration in order to avoid losing MSCs in extraneural 
compartments like liver and lungs. Since the time-course results reveal a slowly declining number of 
MSCs in the cerebroventricular space, it seems that the injected MSCs have a limited time-window 
of permanence in the cerebroventricular spaces of old animals. The rather modest number of Dil(+) 
cells in the brain parenchyma observed in our old rats differs from the findings reported in young rats 
icv injected with BM-MSCs [14]. The study reports that after transplantation, MSCs migrated mainly 
to the ipsilateral DG, CA1 and CA3 regions of the hippocampus, and to a lesser extent, to other 
regions of the brain. The authors used FSL rat-derived BM-MSCs whereas in our study human-
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observed by Tfilin and co-workers in the brain of their rats and the limited migration of hMSC into 
the brain parenchyma of ours. 
Concerning the effect of hBM-MSCs on behavior, our results showing an improvement induced by 
MSC-treatment in old rats on the accuracy to locate the goal sector in the Barnes maze are in line 
with documented evidence of cognitive improvement in mouse and rat models of neurodegenerative 
diseases. Thus, it has been reported that in an acute AD mouse model, intra-hippocampal 
administration of human umbilical cord blood-derived mesenchymal stem cells (hUC-MSCs) 
partially rescued cognitive performance as assessed by the Morris water maze test [37]. In a study 
mentioned above adult rat MSCs were injected (105 cells/bilaterally) into the lateral ventricle of 
Flinders sensitive line (FSL), rats, an animal model for depression. When twelve days later, rats were 
assessed by the forced swim test and the dominant–submissive relationship paradigm, results 
revealed that MSCs-transplanted FSL rats had a significant improvement in their behavioral 
performance in both tests [14].  
Our observation that MSCs-treatment significantly increased the number of DCX neurons in the DG 
of old rats suggests a mild but significant increase in either neurogenesis or mean half-life of 
neuroblasts in this region. Indeed, there is evidence that when implanted in the hippocampal DG of 
rodents, MSCs promote neurogenesis. Thus, it was reported that hMSCs implanted into the 
hippocampal DG of immunodeficient mice induced migration of BrdUrd-labeled endogenous cells 
throughout the dorsal hippocampus (positive for DCX). Some of the cells expressed markers for 
astrocytes and for neural or oligodendrocyte progenitors [9]. In the study by Tfilin et al, 2010, cited 
above, the authors reported that after icv transplantation, neurogenesis was increased in the ipsilateral 
hippocampal DG of engrafted rats (granular cell layer) and was correlated with MSCs engraftment 
and behavioral performance [14]. 
The initial assumption in exploring the mechanisms by which MSCs ameliorate central nervous 
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damaged neural cells [15, 16]. However, more recent studies showed that transplanted MSCs exert 
their therapeutic effect without evidence of engraftment [38–40], which indicates that their 
regenerative and differentiating abilities may not play a role in enhancing tissue repair or limiting 
tissue destruction.  
Furthermore, it is known that when stimulated by inflammatory signals, MSCs secrete a variety of 
bioactive molecules, such as trophic factors and anti-inflammatory molecules able to modulate the 
host microenvironment [41], which is likely to be the main mechanism responsible for their 
therapeutic effects when they are administered iv or icv [42]. Some of the neurotrophic factors 
responsible for these effects are likely to come from the MSCs themselves as suggested by a study in 
which screening a human MSCs cDNA library revealed expressed transcripts encoding BDNF and β-
NGF. Furthermore, immunostaining demonstrated that BDNF and β-NGF proteins were restricted to 
specific MSCs subpopulations, which was confirmed by ELISA analysis of 56 separate subclones of 
hMSCs [5]. Besides, neurotrophic factor-mediated protection was reported following human MSCs 
transplantation into rodent models of neurodegenerative diseases [see an extend revision in Volkman 
& Offen (2017), 43]. Therefore, the possibility exists that neurotrophic factors released by our hBM-
MSCs into the cerebroventricular space reached hippocampal cells thus inducing a moderate 
improvement in function and structure.  
Immune reactivity and inflammatory processes increase with aging in the brain [18], with microglia 
playing a central role in this immune dysregulation [19, 20]. Innate immunity within the central 
nervous system is primarily provided by resident microglia, brain cells that are essential in immune 
surveillance and that also mediate the coordinated responses between the immune system and the 
brain. With normal aging, microglia develop a more reactive phenotype. There are also major 
differences in microglial biology between young and old age when the immune system is challenged, 
and microglia activated. In this context, microglial activation is amplified and prolonged in the aged 
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inflammatory cytokines that exacerbate neuroinflammation, contributing to neuronal loss and 
impairment of cognitive function [19, 20].  
As expected, the number of reactive microglial cells in the Srad of our senile rats was significantly 
higher than in young controls but after hBM-MSC treatment the number of reactive microglial cells 
in the Srad of senile rats was back to young levels. This is in line with evidence that BM-MSCs 
maintain the resting phenotype of microglia and inhibit microglial activation through their 
production of several factors [20]. Neither aging nor MSC treatment appeared to modify the total 
number microglial cells in the Srad of our rats.   
There is growing evidence in support of a relevant role of microglia in synaptic circuit remodeling 
[44–48]. Particularly, it was observed that microglia modulates synapses through elimination of 
presynaptic material [42, 45]. Additionally, a distinctive feature of aging is the cognitive deficit, 
which in the hippocampus correlates with altered synaptic morphology including loss of pre- and 
post-synaptic proteins [49]. The present study revealed a differential expression of synaptic protein 
in the hippocampus of senile rats; specifically, the presynaptic SYT1 and the postsynaptic PSD95 
proteins are decreased. Interestingly, a single MSCs transplantation in these animals restored the 
SYT1 levels to young animal values. This observation is in line with a study in a conventional aging 
model in mice in which hUC-MSCs remarkably enhanced the synaptic plasticity in the CA1 area of 
aged hippocampus [50]. 
 
Conclusions 
We conclude that the restorative action of hBM-MSCs is stronger when they are used in adult 
animals as suggested by the life extension studies described above. The present results suggest that 
when very old rats are treated with hBM-MSCs the restorative effect is milder. Thus, it seems 
plausible to hypothesize that MSCs exert a stabilizing action on brain homeostasis rather than a 
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MSCs from younger donors or umbilical cord-derived MSCs had been used in old rats, the effects 
might have been stronger.  
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Figure 1. Experimental Design and time-course of hBM-MSCs after icv injection. Panel A-
illustrates the experimental design of the study. All animals were submitted to 2 daily acquisition 
trial from experimental day -9 to -6 and to a probe trial on experimental day -5. The hBM-MSCs 
were stereotaxically injected in the LV of Smsc rats on experimental day 0. Yc and Sc remained 
intact. From experimental day 15 to18 all rats received a second (post treatment) series of acquisition 
trial and a probe trial on experimental day 18. On experimental day 21 rats were sacrificed, perfused 
with fixative and the brains removed for morphological analysis. Panel B- Fluorescence microscopy 
of ventricular brain sections at different times after labeled hBM-MSC icv injection. After injection, 
hBM-MSCs numbers in the ventricular spaces declined slowly with most of the cells remaining in 
contact with the ependymal cell layer. A moderate number of Dil-labeled cells can be observed into 
the brain parenchyma near the ependymal cell layer. None was observed near the DG or other brain 
structures distant from the ventricular spaces. Abbreviation: Hab, habituation; LV, lateral ventricle; 
DG, dentate gyrus. Scale bar, 500 µm. 
 
Figure 2. Effect of MSC therapy on hole exploration frequency. At pretreatment (Panel A) both 
groups showed a similar exploratory frequency around hole #0. After treatment (Panel B) the 
exploration frequency of the MSC–treated senile rats for hole # 0 and 1, was significantly higher 
than those of the intact counterparts. Exploration frequency in the other holes remained similar for Sc 
versus Smsc rats for the equivalent holes in the platform. Insets show hole exploration frequency of 
Yc. Notice that hole exploratory frequency in young rats is 2.5-fold higher around the escape hole 
than in the senile counterparts. N=8 per group. All data is represented as mean ± SEM. *P<0.05 














Figure 3. Effect of MSCs treatment on sector exploration frequency. A) Diagrammatic 
representation of Barnes maze sectors (GS1 and GS3). B) GS1 exploratory frequency. The Sc group 
shows no significant pre- versus post-treatment changes, but Smsc rats significantly increased 
exploratory frequency. C) In the GS3 exploratory frequency Sc and Smsc show significant post-
treatment changes namely, a decline for Sc and an increase for Smsc. D) The bar plot represents the 
progression in the GS3 exploratory frequency. It showed a positive progression in the Smsc rats and 
a negative progression in the Sc group. Abbreviations: GS, goal sector. N=8 per group. All data is 
represented as mean ±SEM. *P<0.05: ***, P<0.001.  
 
Figure 4. Doublecortin (DCX) expression in the dentate gyrus (DG) of young intact, senile 
intact and senile+MSCs rats. Images: Coronal sections of the DG in representative animals of Yc 
(A), Sc (B), and Smsc (C) showing DCX neurons. D panel corresponds to a plot showing DCX cell 
numbers in the DG of senile rats. The inset shows DCX cell number in the same hippocampal region 
of Yc rats. Abbreviations: dh, dentate hilus; gcl, granular cell layer; ml, molecular layer. N=4 per 
group. All data is represented as mean ±SEM. Comparisons were made between senile groups, 
*P<0.05. Scale bar: 25 µm. 
 
Figure 5. Iba-1 immunoreactive cells in the Stratum Radiatum of MSC-treated senile rats: 
Coronal sections of the dorsal hippocampus in representative animals of each group showing Iba-1 
immunoreactive cells. Left photomicrographs of Yc (A), Sc (B), and Smsc (C) groups show Iba-1 
positive cells in the Srad. Right plots show the reactive (D), nonreactive (E) and the total number of 
microglia (F) in the Srad in the Yc, Sc, and Smsc rats. Abbreviations: Srad, Stratum radiatum, and 
py, Stratum pyramidale. N=4 per group. All data is represented as mean ± SEM. Comparisons were 













Figure 6. MSCs therapy effect on rat hippocampal protein levels. Images of VIN, SYT1, SYP, 
PSD95, and β-actin hippocampus protein levels of each animal (A). Quantification of protein levels 
of SYP (B), SYT1 (C), normalized to the relative density of VIN, and PSD95 (D) normalized to the 
relative density of β-actin. A significant decrease in SYT1 and PSD95 protein levels was observed in 
the Sc rats, while cell therapy led to a recovery of SYT1 level in the Smsc rats. SYP protein levels 
tend to decrease in the Sc group, but no significant differences are observed between both 
experimental groups. Abbreviation: VIN, Vinculin; SYT1, synaptotagmin 1; SYP, synaptophysin; 
PSD95, postsynaptic density protein 95. N=4 per group. All data is represented as mean ±SEM. 
Comparisons were made between groups, *P<0.05; ***P<0.001. 
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